This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...

In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at ...

Sales of Voxzogo for achondroplasia grew more than a quarter in 2025 to reach $927 million, making it BioMarin's biggest seller, but the company has predicted that growth will slow in 2026, with a ...

NYSE-listed Alto Neuroscience has raised $120 million in a private placement that will be used to advance its recently acquired candidate for treatment-resistant depression (TRD) into a pivotal trials ...

A patient advocacy group in the UK is calling for changes to the decade-old meningitis vaccination programme, after an outbreak in Kent that has killed two young people and left nearly a dozen others ...

Roche has ramped up its investment in NVIDIA's AI chips, launching an upscaled hybrid-cloud AI factory that it believes is ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

A federal judge has pushed back against attempts by HHS Secretary Robert F Kennedy Jr to overhaul immunisation policy in the US, blocking changes to the recommended schedule as well as his ...

Rentschler taps biopharma vet to lead ops. Rentschler Biopharma, the German CDMO with offices in Massachusetts and Stevenage, ...

In order to discuss this topic further, pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata ...

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with ...